Missionomics Back to app

Healthcare

Haemonetics Corporation (HAE)

Healthcare $3.5B market cap

Data as of July 16, 2026

Environment
65.00
People
78.00
Leadership
72.00

Environment story

Haemonetics demonstrates moderate environmental performance with acknowledged climate risks but limited disclosed emissions data. The company recognizes climate change impacts on supply chains and regulatory compliance costs, particularly regarding ethylene oxide sterilization regulation. However, no verified Scope 1, 2, or 3 emissions baselines, reduction targets, or net-zero commitments are disclosed in the 10-K. The company acknowledges increasing regulatory burdens from climate legislation but provides no quantified decarbonization initiatives or renewable energy investments. Supply chain vulnerability to climate-related disruptions (extreme weather, resource availability) is acknowledged but not comprehensively addressed. Absence of third-party sustainability reporting or validated emissions data prevents higher scoring.

Criticisms on file

  • No disclosed Scope 1, 2, or 3 emissions baseline or net-zero target; absence of validated climate commitments
    Source: HAE 10-K FY2026, Risk Factors section; no sustainability report provided
  • Heavy reliance on ethylene oxide sterilization with regulatory scrutiny but no alternative sterilization transition plan disclosed
    Source: HAE 10-K FY2026, Risks Related to Government Regulation section

Disclosed initiatives

  • Ethylene Oxide Sterilization Compliance
    Company acknowledges EPA focus on reducing emissions from ethylene oxide sterilization process and associated regulatory requirements.
    Compliance obligation; cost and operational impact not quantified.
  • Climate Risk Acknowledgment in Supply Chain
    10-K discloses awareness of climate change impacts on raw material availability, pricing, and manufacturing disruptions.
    Risk management posture; no proactive decarbonization infrastructure disclosed.

Social story

Haemonetics demonstrates partial disclosure of social responsibility practices. The company acknowledges importance of talent retention and competitive compensation, with recognition of hybrid work policies and succession planning as competitive factors. However, the 10-K does not disclose CEO-to-median-worker pay ratio, comprehensive diversity metrics for leadership or workforce, turnover rates, or union relationships. No documented labor disputes or union-suppression activities are mentioned in available materials. Supply chain human-rights audits, particularly regarding conflict minerals or high-risk geographies, are not disclosed. The company identifies corporate responsibility initiatives as strategically important but does not quantify progress on diversity, pay equity, or supply-chain ethics. Limited disclosure prevents full assessment of social performance.

Criticisms on file

  • No disclosed CEO-to-median-worker pay ratio, workforce diversity breakdown, or gender/racial pay gap analysis
    Source: HAE 10-K FY2026; no DEI disclosures in proxy or sustainability reporting
  • Supply chain human-rights practices not disclosed; no conflict minerals, living wage, or modern slavery statement referenced
    Source: HAE 10-K FY2026, no supply-chain ethics section

Disclosed initiatives

  • Key Personnel Recruitment and Retention
    Company emphasizes importance of attracting and retaining talent in senior management, sales, marketing and R&D; acknowledges hybrid work environment policies as competitive factor.
    Organizational capability; no quantified retention metrics disclosed.
  • Corporate Responsibility Initiatives (Unspecified)
    Company acknowledges evolving stakeholder expectations on ESG matters and announces corporate responsibility initiatives and goals, but specific diversity, pay equity, or supply-chain ethics programs are not detailed in 10-K.
    Strategic positioning; lack of transparency on implementation and outcomes.
  • Succession Planning
    Company recognizes importance of seamless leadership transitions for key positions.
    Governance continuity; effectiveness not disclosed.

Governance story

Haemonetics demonstrates moderate governance structure with disclosed board and shareholder protections but limited transparency on lobbying and regulatory compliance. The company operates with standard corporate governance frameworks (SEC compliance, audit committees) and acknowledges anti-corruption compliance programs targeting FCPA and similar laws. However, board independence percentage is not disclosed in 10-K, share structure (single vs. dual-class) is not explicitly stated, and annual lobbying expenditures are not reported. The company acknowledges substantial debt obligations and convertible note provisions that could complicate takeover defenses. No material antitrust, consumer-safety, or financial-fraud regulatory proceedings are disclosed as active, but the company discloses product liability litigation exposure and IP litigation. Shareholder proposals and voting outcomes are not summarized in provided 10-K excerpt. Limited public disclosure of political positions and lobbying alignment restricts higher scoring.

Criticisms on file

  • Board independence percentage not disclosed; no proxy statement excerpt provided
    Source: HAE 10-K FY2026
  • Share structure (single vs. dual-class voting) not explicitly disclosed in 10-K excerpt; no founder voting supermajority mentioned
    Source: HAE 10-K FY2026
  • Annual lobbying expenditures not disclosed; no quantified political spending or PAC contribution data provided
    Source: HAE 10-K FY2026
  • Convertible notes (2029 and prior 2026 notes) include provisions that could delay or prevent takeover; noteholders retain fundamental change repurchase rights
    Source: HAE 10-K FY2026, Risks Related to Financial Obligations section

Disclosed initiatives

  • Foreign Corrupt Practices Act (FCPA) Compliance Program
    Company discloses active compliance program and safeguards to prevent impermissible practices in 87-country distribution network, acknowledging FCPA and similar anti-corruption laws.
    Risk mitigation in high-corruption-risk geographies; program effectiveness not independently verified.
  • Shareholder Value and Capital Allocation
    Company maintains $500 million share repurchase authorization (approved April 2025, extends through April 2028) and convertible note program; acknowledges potential impacts on stock price and shareholder dilution.
    Capital allocation transparency; acknowledges shareholder risk from conversion dilution and repurchase volatility.
  • Debt and Financial Covenant Compliance
    Company operates under 2024 Revised Credit Facilities with financial covenants; discloses compliance status as of March 28, 2026, and forecasts continued compliance through April 3, 2027.
    Financial stability and covenant monitoring; refinancing completed in 2024.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Haemonetics Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Haemonetics Corporation in the app for interactive charts and portfolio building.

Open Haemonetics Corporation in Missionomics

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)

Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics